Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Inclusion Criteria: * Diagnosis of T cell non-Hodgkin lymphoma, T cell lymphomas included are peripheral T cell lymphoma not otherwise specified, angioimmunoblastic T cell lymphoma, and systemic anaplastic large cell lymphoma. * Eligible for autologous stem cell transplantation as determined by the treating physician or completed autologous transplant within the last 30 days. * At least 18 years of age at time of enrollment * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Adequate organ function as defined below: * Serum creatinine ≤ 1.5 times institutional upper limit of normal (IULN) * Total bilirubin ≤ 1.5 x IULN. Patients with Gilbert's Syndrome may have a bilirubin \> 1.5 x IULN * Hemoglobin ≥ 8.0 g/dL * Absolute neutrophil count ≥ 1.0 x 109/L * Platelet count ≥ 75 x 109/L * AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN * Women of childbearing potential and men must agree to use highly effective contraception prior to study entry and for the duration of study participation and for 3 months after the last dose of duvelisib. Negative serum β human chorionic gonadotropin (βHCG) pregnancy test within 7 days before first treatment is required if the patient is a woman of childbearing potential. * Participants or a participant's legally authorized representative must be able to understand and willing to sign an IRB approved written informed consent document Exclusion Criteria: * Currently receiving any other experimental therapy or has received experimen…